Takara Bio UK Ltd
Registered name: TAKARA BIO UK LTD
Takara Bio UK Ltd made £3.1m revenue and £97.2k profit in the year to 31 Dec 2025.
Takara Bio UK Ltd’s revenue grew 21% to £3.1m in the year to 31 Dec 2025, with £97.2k profit and 9 employees. The company is classified under “research and experimental development on biotechnology” and is based in London; we hold 3 years of its filed accounts.
- Status
- Active
- Location
- London, London
- Age
- 5 yrs · since 2021
- Type
- Private Limited Company
Key figures
Badges are automated estimates derived from the filed figures — not statements of fact about the company.
Financial history
| Year to | 31 Dec 2023 | 31 Dec 2024 | 31 Dec 2025 |
|---|---|---|---|
| Disclosure | Full P&L | Full P&L | Full P&L |
| Profit & loss | |||
| Revenue (turnover) | £2.2m | £2.5m | £3.1m |
| Cost of sales | −£358k | −£781k | −£1.4m |
| Gross profit | £1.8m | £1.7m | £1.6m |
| Operating profit | £312k | −£10.1k | £122k |
| Profit before tax | £312k | −£10.1k | £122k |
| Profit after tax | £238k | −£9.8k | £97.2k |
| Profit (best available) | £238k | −£9.8k | £97.2k |
| Employees (average) | 7 | 9 | 9 |
| Ratios | |||
| Profit margin | 11% | −0.4% | 3.2% |
| Gross margin | 83.5% | 69% | 53.9% |
| Revenue per employee | £310k | £280k | £340k |
| Profit per employee | £34k | −£1.1k | £10.8k |
| Growth (year on year) | |||
| Revenue growth | — | ▲16.1% | ▲21.4% |
| Profit growth | — | ▼104.1% | — |
| Headcount growth | — | ▲28.6% | 0% |
| Balance sheet — indirect signals, not revenue | |||
| Net assets | — | — | — |
| Source | Accounts · bulk data Sep 2025 | Accounts · bulk data Sep 2025 | Accounts · bulk data Apr 2026 |
How the business works
- Profit margin
- 3.2%
- Profit ÷ revenue.
- Gross margin
- 53.9%
- Gross profit ÷ revenue. High for software and services.
- Revenue per employee
- £340k
- Revenue ÷ average employees.
- Profit per employee
- £10.8k
- Profit ÷ average employees.
- Cash conversion
- —
- Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
- Fixed assets ÷ revenue
- —
- Capital intensity. Low = capital-light, cheaper to start.
- Deferred income ÷ revenue
- —
- Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
- Debtors ÷ revenue
- —
- Money owed by customers. Low = customers pay quickly.
Balance-sheet signals
Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.
- Net assets
- —
- Now —
- Cash at bank
- —
- Now —
- Headcount
- 0%
- Now 9
- Deferred income
- —
- Now —
- Fixed assets
- —
- Now —
Similar profitable businesses
- Clinuvel (UK) LimitedLondon · Research and experimental development on biotechnology
- Revenue
- £6.4m
- Profit
- £81.6k
- Staff
- 46
- Clinicology Ltd.Guildford · Research and experimental development on biotechnology
- Revenue
- £1.4m
- Profit
- £79.1k
- Staff
- 7
- Adorx Therapeutics LimitedEdinburgh · Research and experimental development on biotechnology
- Revenue
- £1.2m
- Profit
- £211k
- Staff
- 0
- Nuritas UK LimitedLondon · Research and experimental development on biotechnology
- Revenue
- £1.2m
- Profit
- £88.8k
- Staff
- 4
- Ligand UK Development LimitedLondon · Research and experimental development on biotechnology
- Revenue
- £8.7m
- Profit
- £6m
- Staff
- —
Sources
Latest figures from accounts for the year to 31 Dec 2025 (profit £97.2k), from the Companies House accounts bulk data published Apr 2026. Spotted an error? Request a correction.
Updated from Companies House on 13 Oct 2026
Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.